Balyasny Asset Management’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-951,165
| Closed | -$80.9M | – | 1876 |
|
|
2020
Q3 | $80.9M | Buy |
+951,165
| New | +$48.1M | 0.59% | 19 |
|
|
2020
Q2 | – | Sell |
-14,266
| Closed | -$192K | – | 1624 |
|
|
2020
Q1 | $192K | Buy |
+14,266
| New | +$240K | ﹤0.01% | 1052 |
|
|
2019
Q1 | – | Sell |
-11,520
| Closed | -$164K | – | 1771 |
|
|
2018
Q4 | $164K | Buy |
+11,520
| New | +$229K | ﹤0.01% | 1313 |
|
|
2018
Q3 | – | Sell |
-390,185
| Closed | -$9.24M | – | 2196 |
|
|
2018
Q2 | $9.24M | Buy |
+390,185
| New | +$7.84M | 0.04% | 511 |
|
|
2017
Q4 | – | Sell |
-235,687
| Closed | -$3.29M | – | 2441 |
|
|
2017
Q3 | $3.29M | Buy |
+235,687
| New | +$2.35M | 0.01% | 843 |
|
|
2016
Q4 | – | Sell |
-1,569,885
| Closed | -$5.1M | – | 1543 |
|
|
2016
Q3 | $5.1M | Buy |
1,569,885
+474,209
| +43% | +$1.33M | 0.03% | 496 |
|
|
2016
Q2 | $2.54M | Sell |
1,095,676
-988,636
| -47% | -$3.3M | 0.02% | 645 |
|
|
2016
Q1 | $5.21M | Sell |
2,084,312
-174,782
| -8% | -$393K | 0.03% | 531 |
|
|
2015
Q4 | $6.93M | Buy |
2,259,094
+255,016
| +13% | +$712K | 0.05% | 437 |
|
|
2015
Q3 | $3.45M | Buy |
+2,004,078
| New | +$5.12M | 0.03% | 580 |
|
Balyasny Asset Management's IMMU Position: Q4 2020 in Review
Balyasny Asset Management sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 951,165 shares — an estimated $80.9M sold.
Balyasny Asset Management first reported a position in IMMU in Q3 2015 and held it in 10 quarters. The position peaked at $80.9M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Balyasny Asset Management reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Balyasny Asset Management sold 951,165 Immunomedics Inc shares in Q4 2020, an estimated $80.9M.
- Balyasny Asset Management first reported a position in Immunomedics Inc in Q3 2015 and held it in 10 quarters.
- Balyasny Asset Management's Immunomedics Inc position peaked at $80.9M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Balyasny Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.